Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standardized shortened regimen versus locally used WHO-approved regimen for MDR-TB
ISRCTN78372190Phase 3Completed
- Sponsor
- International Union Against Tuberculosis and Lung Disease
- Start
- Nov 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of moxifloxacin, clofazimine, ethambutol, pyrazinamide, kanamycin and 2 more in pulmonary tuberculosis (TB) (2 arms), sponsored by International Union Against Tuberculosis and Lung Disease. Primary endpoints: Favourable efficacy outcome at 132 weeks after randomisation and Grade 3 or greater adverse events. Started Nov 2011; status: completed.
02
Drugs
moxifloxacinclofazimineethambutolpyrazinamidekanamycin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ISRCTN78372190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78372190.